NeuroSense rises 16% on U.S. FDA clearance to begin trial of ALS treatment

Nov. 15, 2022 9:12 AM ETNeuroSense Therapeutics Ltd. (NRSN)By: Dania Nadeem, SA News Editor

ALS acronym on colorful wooden cubes

chrupka/iStock via Getty Images

  • NeuroSense Therapeutics (NASDAQ:NRSN) is trading 16.5% higher after it said on Tuesday the U.S. Food and Drug Administration had cleared its Investigational New Drug to begin trial of Phase 2b study for its lead

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.